Radiology Devices; Reclassification of Digital Breast Tomosynthesis System
FDA proposes reclassifying digital breast tomosynthesis (DBT) systems from class III to class II, potentially easing regulatory burdens for manufacturers.
Aforeworn detected this change in the Healthcare AI Regulation (FDA / ONC) space on August 8, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Manufacturers of digital breast tomosynthesis systems (product code OTE), including medical device companies and health tech startups. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Comment period deadline not specified in the excerpt; check the Federal Register document for details.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Healthcare AI Regulation (FDA / ONC) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The FDA is proposing to reclassify DBT systems from class III (requiring premarket approval) to class II, which may allow a streamlined 510(k) pathway.
Who it affects
Manufacturers of digital breast tomosynthesis systems (product code OTE), including medical device companies and health tech startups.
What you must do
Monitor the rulemaking process and prepare for potential changes in regulatory submission requirements.
Deadline
Comment period deadline not specified in the excerpt; check the Federal Register document for details.
Never miss a change like this again
Aforeworn watches Healthcare AI Regulation (FDA / ONC) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Healthcare AI Regulation (FDA / ONC)
- CO SB26-189: Automated Decision-Making Technology
- Medical Devices; Radiology Devices; Classification of the Fludeoxyglucose F18-Guided Radiation Therapy System
- US-CONGRESS BILLS-119s3097rs: Health Information Privacy Reform Act
- US-CONGRESS BILLS-119hr9693ih: Patients First Act of 2026
- US-CONGRESS S4916: Aging with Artificial Intelligence Act of 2026